Skip to content
Dexlansoprazole
Dexilant (dexlansoprazole) is a small molecule pharmaceutical. Dexlansoprazole was first approved as Dexilant on 2009-01-30. It is used to treat gastroesophageal reflux, heartburn, and peptic esophagitis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dexilant (generic drugs available since 2017-04-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dexlansoprazole
Tradename
Company
Number
Date
Products
DEXILANTTakedaN-022287 RX2009-01-30
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dexilantNew Drug Application2023-04-21
dexlansoprazole ANDA2023-05-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gastroesophageal refluxEFO_0003948D005764K21
heartburn—D006356R12
peptic esophagitisEFO_1001095D004942—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dexlansoprazole, Dexilant, Takeda Pharms Usa
92331032032-03-05U-1805
81731582030-03-17U-949, U-950, U-951
88712732028-01-11DP
81056262026-09-27DP
77907552026-08-02DP
90119262026-02-24DP
84611872026-01-17DP
92380292026-01-17DP
87220842023-10-15DP
87848852023-10-15DPU-1552, U-1553, U-1554
66642762023-01-30DS, DPU-949, U-950, U-951, U-1507
Dexlansoprazole, Dexilant Solutab, Takeda Pharms Usa
92419102029-03-10DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC06: Dexlansoprazole
HCPCS
No data
Clinical
Clinical Trials
212 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastroesophageal refluxD005764EFO_0003948K211061114846
Healthy volunteers/patients—26——4—30
EsophagitisD004941HP_0100633K202593—19
Stomach ulcerD013276K25——111113
InfectionsD007239EFO_0000544——37111
Peptic ulcerD010437HP_0004398K27——3418
HeartburnD006356R122132—8
Laryngopharyngeal refluxD057045EFO_10013551——337
Peptic esophagitisD004942EFO_1001095—151—7
AsthmaD001249EFO_0000270J45—122—4
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Duodenal ulcerD004381EFO_0004607K26——10—212
Breast neoplasmsD001943EFO_0003869C50—21——3
Type 1 diabetes mellitusD003922EFO_0001359E10—21——3
GoutD006073EFO_0004274M10—11——2
OsteoarthritisD010003EFO_0002506M15-M19——1——1
Human experimentationD006805——1——1
Helicobacter infectionsD016481EFO_1000961——1——1
Idiopathic pulmonary fibrosisD054990J84.112——1——1
Respiratory tract infectionsD012141J06.9——1——1
PneumoniaD011014EFO_0003106J18——1——1
Show 1 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Endometrial neoplasmsD016889EFO_0004230—1———1
Uterine neoplasmsD014594EFO_0003859C55—1———1
Uterine cervical neoplasmsD002583—1———1
Renal insufficiencyD051437HP_0000083N19—1———1
Avulsion fracturesD00007156211———1
Appendiceal neoplasmsD001063EFO_0003880C18.1—1———1
Pseudomyxoma peritoneiD011553EFO_0007456—1———1
B-cell chronic lymphocytic leukemiaD015451C91.1—1———1
Deglutition disordersD003680HP_0002015R13.111———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HomeostasisD0067061————1
Biological availabilityD0016821————1
Mouth neoplasmsD009062EFO_0003868C06.91————1
Cystic fibrosisD003550EFO_0000390E841————1
Therapeutic equivalencyD0138101————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aortic valve diseaseD000082862————11
Coronary artery diseaseD003324I25.1————11
GlomerulonephritisD005921N05————11
Membranous glomerulonephritisD015433EFO_0004254N03.2————11
Nephrotic syndromeD009404EFO_0004255N04————11
Neuroendocrine carcinomaD018278————11
Head and neck neoplasmsD006258————11
Oropharyngeal neoplasmsD009959————11
Peptic ulcer hemorrhageD010438————11
Nasal polypsD009298HP_0100582J33————11
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEXLANSOPRAZOLE
INNdexlansoprazole
Description
Dexlansoprazole is a sulfoxide and a member of benzimidazoles.
Classification
Small molecule
Drug classantiulcer agents (benzimidazole derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1
Identifiers
PDB—
CAS-ID138530-94-6
RxCUI816346
ChEMBL IDCHEMBL1201863
ChEBI ID—
PubChem CID9578005
DrugBankDB05351
UNII IDUYE4T5I70X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Dexilant - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 648 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
65,322 adverse events reported
View more details